

# Robin Emsley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7779601/publications.pdf>

Version: 2024-02-01

139  
papers

5,389  
citations

87888

38  
h-index

91884

69  
g-index

145  
all docs

145  
docs citations

145  
times ranked

5498  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antipsychotic treatment effects and structural MRI brain changes in schizophrenia. <i>Psychological Medicine</i> , 2023, 53, 2050-2059.	4.5	3
2	Hair cortisol levels in schizophrenia and metabolic syndrome. <i>Microbial Biotechnology</i> , 2022, 16, 902-911.	1.7	7
3	The associations of cannabis and methamphetamine use with cognitive performance over the first 2 years of treatment in schizophrenia spectrum disorders. <i>Microbial Biotechnology</i> , 2022, 16, 1230-1239.	1.7	1
4	RNA-seq analysis of gene expression profiles in posttraumatic stress disorder, Parkinson's disease and schizophrenia identifies roles for common and distinct biological pathways. <i>Discover Mental Health</i> , 2022, 2, .	2.0	4
5	The trajectories and correlates of two negative symptom subdomains in first-episode schizophrenia. <i>Schizophrenia Research</i> , 2022, 243, 17-23.	2.0	5
6	Sex and gender associations with indicators of neurodevelopmental compromise in schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2022, 243, 70-77.	2.0	5
7	Childhood trauma exposure and reward processing in healthy adults: A functional neuroimaging study. <i>Journal of Neuroscience Research</i> , 2022, 100, 1452-1462.	2.9	7
8	Spontaneous and emergent extrapyramidal syndromes in Black Africans with first-episode schizophrenia and first exposure to antipsychotics. <i>Journal of Mental Health</i> , 2021, 30, 240-245.	1.9	3
9	Extrapyramidal side effects in first-episode schizophrenia treated with flupenthixol decanoate. <i>South African Journal of Psychiatry</i> , 2021, 27, 1568.	0.4	0
10	Factors associated with dropout at 2 years post-initiation of treatment in the first episode of schizophrenia. <i>South African Journal of Psychiatry</i> , 2021, 27, 1657.	0.4	1
11	Cognitive insight is associated with perceived body weight in overweight and obese adults. <i>BMC Public Health</i> , 2021, 21, 534.	2.9	2
12	The course and concomitants of depression in first-episode schizophrenia spectrum disorders: A 24-month longitudinal study. <i>Psychiatry Research</i> , 2021, 298, 113767.	3.3	4
13	Cannabis use and clinical outcome in people with first-episode schizophrenia spectrum disorders over 24 months of treatment. <i>Psychiatry Research</i> , 2021, 302, 114022.	3.3	6
14	Childhood trauma and hippocampal subfield volumes in first-episode schizophrenia and healthy controls. <i>Schizophrenia Research</i> , 2020, 215, 308-313.	2.0	11
15	Early recovery in the first 24 months of treatment in first-episode schizophrenia-spectrum disorders. <i>NPJ Schizophrenia</i> , 2020, 6, 2.	3.6	40
16	Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. <i>Schizophrenia Research</i> , 2020, 225, 55-62.	2.0	23
17	Guest editorial: Special issue on maintenance treatment in schizophrenia. <i>Schizophrenia Research</i> , 2020, 225, 1-3.	2.0	2
18	Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. <i>BMC Medicine</i> , 2020, 18, 215.	5.5	52

#	ARTICLE	IF	CITATIONS
19	Sex versus gender as risk factors for the age of onset of schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2020, 220, 267-268.	2.0	3
20	The association between childhood trauma and treatment outcomes in schizophrenia spectrum disorders. <i>Psychiatry Research</i> , 2020, 289, 113004.	3.3	7
21	Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532098150.	2.7	3
22	Childhood Trauma Associated White Matter Abnormalities in First-Episode Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019, 45, 369-376.	4.3	22
23	Variation within voltage-gated calcium channel genes and antipsychotic treatment response in a South African first episode schizophrenia cohort. <i>Pharmacogenomics Journal</i> , 2019, 19, 109-114.	2.0	7
24	Prolactin, flupenthixol decanoate and first episode schizophrenia – clinical and laboratory correlates. <i>Metabolic Brain Disease</i> , 2019, 34, 1679-1687.	2.9	6
25	The Potential Role of Regulatory Genes (DNMT3A, HDAC5, and HDAC9) in Antipsychotic Treatment Response in South African Schizophrenia Patients. <i>Frontiers in Genetics</i> , 2019, 10, 641.	2.3	3
26	10Kin1day: A Bottom-Up Neuroimaging Initiative. <i>Frontiers in Neurology</i> , 2019, 10, 425.	2.4	15
27	Changes in insight over the first 24 months of treatment in schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2019, 206, 394-399.	2.0	18
28	Modification of the association between antipsychotic treatment response and childhood adversity by MMP9 gene variants in a first-episode schizophrenia cohort. <i>Psychiatry Research</i> , 2018, 262, 141-148.	3.3	18
29	The genetic architecture of schizophrenia, bipolar disorder, obsessive-compulsive disorder and autism spectrum disorder. <i>Molecular and Cellular Neurosciences</i> , 2018, 88, 300-307.	2.2	70
30	Factors associated with placebo response in depression trials: A systematic review of published meta-analyses (1990–2017). <i>Neurology Psychiatry and Brain Research</i> , 2018, 30, 12-21.	2.0	3
31	Reward processing dysfunction in ventral striatum and orbitofrontal cortex in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 82-88.	2.2	13
32	Symptom attribution and frontal cortical thickness in first-episode schizophrenia. <i>Microbial Biotechnology</i> , 2018, 12, 652-659.	1.7	17
33	Discontinuing antipsychotic treatment after a first-episode of psychosis: Who, when and how?. <i>Schizophrenia Research</i> , 2018, 197, 59-60.	2.0	3
34	Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders. <i>International Clinical Psychopharmacology</i> , 2018, 33, 15-33.	1.7	11
35	Antipsychotic maintenance treatment in schizophrenia and the importance of preventing relapse. <i>World Psychiatry</i> , 2018, 17, 168-169.	10.4	11
36	Neurological Soft Signs, Spontaneous and Treatment Emergent Extrapyrmidal Syndromes in Black Africans With First Episode Schizophrenia. <i>Frontiers in Psychiatry</i> , 2018, 9, 172.	2.6	7

#	ARTICLE	IF	CITATIONS
37	The expression of neurological soft signs in two African populations with first-episode schizophrenia. <i>Transcultural Psychiatry</i> , 2018, 55, 669-688.	1.6	3
38	Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 205-223.	2.2	16
39	Efficacy of Tianeptine 25â€“50 mg in Elderly Patients With Recurrent Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	2.2	8
40	Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	2.2	29
41	Prevalence and clinical correlates of police contact prior to a first diagnosis of schizophrenia. <i>Criminal Behaviour and Mental Health</i> , 2017, 27, 27-39.	0.8	3
42	Neurological soft signs in first-episode schizophrenia: State- and trait-related relationships to psychopathology, cognition and antipsychotic medication effects. <i>Schizophrenia Research</i> , 2017, 188, 144-150.	2.0	22
43	Proposing the short Neurological Evaluation Scale. <i>Acta Neuropsychiatrica</i> , 2017, 29, 236-243.	2.1	2
44	Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2017, 32, 235-248.	1.7	19
45	On discontinuing treatment in schizophrenia: a clinical conundrum. <i>NPJ Schizophrenia</i> , 2017, 3, 4.	3.6	6
46	Insight and white matter fractional anisotropy in first-episode schizophrenia. <i>Schizophrenia Research</i> , 2017, 183, 88-94.	2.0	19
47	Once-monthly paliperidone palmitate in early stage schizophrenia &ndash; a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2261-2269.	2.2	8
48	Cognitive-perceptual deficits and symptom correlates in first-episode schizophrenia. <i>South African Journal of Psychiatry</i> , 2017, 23, 1049.	0.4	4
49	Forensic mental health services: Current service provision and planning for a prison mental health service in the Eastern Cape. <i>South African Journal of Psychiatry</i> , 2016, 22, 5.	0.4	8
50	How long should antipsychotic treatment be continued after a single episode of schizophrenia?. <i>Current Opinion in Psychiatry</i> , 2016, 29, 224-229.	6.3	16
51	Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia. <i>BMJ, The</i> , 2016, 354, i4728.	6.0	4
52	Recommendations for the optimal care of patients with recentâ€“onset psychosis in the <sc>Asia-Pacific</sc> region. <i>Asia-Pacific Psychiatry</i> , 2016, 8, 154-171.	2.2	24
53	Posttraumatic Stress Disorder, Overweight, and Obesity: A Systematic Review and Meta-analysis. <i>Harvard Review of Psychiatry</i> , 2016, 24, 271-293.	2.1	32
54	Prefrontal cortical thinning in HIV infection is associated with impaired striatal functioning. <i>Journal of Neural Transmission</i> , 2016, 123, 643-651.	2.8	20

#	ARTICLE	IF	CITATIONS
55	Exploratory factor structure of the neurological evaluation scale in black africans with first episode schizophrenia. Data in Brief, 2016, 6, 471-475.	1.0	2
56	Combining depot antipsychotic with an assertive monitoring programme for treating first-episode schizophrenia in a resource-constrained setting. Microbial Biotechnology, 2016, 10, 54-62.	1.7	22
57	Remission and employment status in schizophrenia and other psychoses: One-year prospective study in Croatian patients treated with risperidone long acting injection. Psychiatria Danubina, 2016, 28, 263-272.	0.4	6
58	HIV Infection Is Associated with Impaired Striatal Function during Inhibition with Normal Cortical Functioning on Functional MRI. Journal of the International Neuropsychological Society, 2015, 21, 722-731.	1.8	18
59	HIV infection results in ventral-striatal reward system hypo-activation during cue processing. Aids, 2015, 29, 1335-1343.	2.2	16
60	Rate and predictors of non-response to first-line antipsychotic treatment in first-episode schizophrenia. Human Psychopharmacology, 2015, 30, 173-182.	1.5	30
61	Instruments Measuring Blunted Affect in Schizophrenia: A Systematic Review. PLoS ONE, 2015, 10, e0127740.	2.5	9
62	Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey. Therapeutic Advances in Psychopharmacology, 2015, 5, 339-350.	2.7	14
63	Changes in brain regions associated with food-intake regulation, body mass and metabolic profiles during acute antipsychotic treatment in first-episode schizophrenia. Psychiatry Research - Neuroimaging, 2015, 233, 186-193.	1.8	12
64	The confirmatory factor structure of neurological soft signs in Nigerians with first episode schizophrenia. Neuroscience Letters, 2015, 589, 110-114.	2.1	6
65	Dorsal striatal volumes in never-treated patients with first-episode schizophrenia before and during acute treatment. Schizophrenia Research, 2015, 169, 89-94.	2.0	17
66	Motor sequencing abnormalities are the trait marking neurological soft signs of schizophrenia. Neuroscience Letters, 2015, 600, 226-231.	2.1	18
67	HIV infection and the fronto-striatal system. Aids, 2014, 28, 803-811.	2.2	107
68	Re: Less is more. Schizophrenia Research, 2014, 160, 224-225.	2.0	1
69	Towards a treatment model for family therapy for schizophrenia in an urban African setting: Results from a qualitative study. International Journal of Social Psychiatry, 2014, 60, 315-320.	3.1	23
70	Alcohol-induced psychotic disorder: a review. Metabolic Brain Disease, 2014, 29, 231-243.	2.9	60
71	A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Schizophrenia Research, 2014, 158, 230-235.	2.0	52
72	Patterns of variation influencing antipsychotic treatment outcomes in South African first-episode schizophrenia patients. Pharmacogenomics, 2014, 15, 189-199.	1.3	17

#	ARTICLE	IF	CITATIONS
73	The nature of relapse in schizophrenia. <i>BMC Psychiatry</i> , 2013, 13, 50.	2.6	323
74	Improving Treatment Adherence in Your Patients with Schizophrenia. <i>Clinical Drug Investigation</i> , 2013, 33, 97-107.	2.2	38
75	Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine. <i>Brain, Behavior, and Immunity</i> , 2013, 30, 156-167.	4.1	150
76	Is the ongoing use of placebo in relapse-prevention clinical trials in schizophrenia justified?. <i>Schizophrenia Research</i> , 2013, 150, 427-433.	2.0	17
77	The evidence for illness progression after relapse in schizophrenia. <i>Schizophrenia Research</i> , 2013, 148, 117-121.	2.0	109
78	Long-acting injectable antipsychotics in early psychosis: a literature review. <i>Microbial Biotechnology</i> , 2013, 7, 247-254.	1.7	46
79	Psychiatrists' awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa. <i>Patient Preference and Adherence</i> , 2013, 7, 121.	1.8	25
80	Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine. <i>International Clinical Psychopharmacology</i> , 2013, 28, 20-28.	1.7	18
81	Comparison of Treatment Response in Second-Episode Versus First-Episode Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 80-83.	1.4	62
82	Non-adherence and its consequences: understanding the nature of relapse. <i>World Psychiatry</i> , 2013, 12, 234-235.	10.4	7
83	Early intervention in schizophrenia in developing countries: Focus on duration of untreated psychosis and remission as a treatment goal. <i>International Review of Psychiatry</i> , 2012, 24, 483-488.	2.8	24
84	Social isolation rearing in rats alters plasma tryptophan metabolism and is reversed by sub-chronic clozapine treatment. <i>Neuropharmacology</i> , 2012, 62, 2499-2506.	4.1	30
85	Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. <i>Schizophrenia Research</i> , 2012, 138, 29-34.	2.0	82
86	Alcohol-induced psychotic disorder: brain perfusion and psychopathology "before and after anti-psychotic treatment. <i>Metabolic Brain Disease</i> , 2012, 27, 67-77.	2.9	21
87	Symptom Recurrence Following Intermittent Treatment in First-Episode Schizophrenia Successfully Treated for 2 Years. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e541-e547.	2.2	60
88	Isolation rearing-induced deficits in sensorimotor gating and social interaction in rats are related to cortico-striatal oxidative stress, and reversed by sub-chronic clozapine administration. <i>European Neuropsychopharmacology</i> , 2011, 21, 471-483.	0.7	97
89	The concepts of remission and recovery in schizophrenia. <i>Current Opinion in Psychiatry</i> , 2011, 24, 1.	6.3	88
90	Exposure to trauma and the clinical presentation of first-episode psychosis in South Africa. <i>Journal of Psychiatric Research</i> , 2011, 45, 179-184.	3.1	22

#	ARTICLE	IF	CITATIONS
91	16th National Congress of the South African Society of Psychiatrists (SASOP). South African Journal of Psychiatry, 2010, 16, 29.	0.4	0
92	Pathways to Inpatient Mental Health Care Among People With Schizophrenia Spectrum Disorders in South Africa. Psychiatric Services, 2010, 61, 235-240.	2.0	22
93	The quest for a meaningful evidence base in psychiatry. World Psychiatry, 2009, 8, 33-34.	10.4	4
94	Early response to treatment predicts remission and recovery at 3 years in people with schizophrenia. Evidence-Based Mental Health, 2009, 12, 43-43.	4.5	2
95	Changes in erythrocyte membrane fatty acids during a clinical trial of eicosapentaenoic acid (EPA) supplementation in schizophrenia. Metabolic Brain Disease, 2009, 24, 659-672.	2.9	19
96	New advances in pharmacotherapy for early psychosis. Microbial Biotechnology, 2009, 3, S8-12.	1.7	5
97	Drugs in development for the treatment of schizophrenia. Expert Opinion on Investigational Drugs, 2009, 18, 1103-1118.	4.1	27
98	Bilingualism and psychosis: a linguistic analysis of a patient with differential symptom severity across languages. Southern African Linguistics and Applied Language Studies, 2009, 27, 163-171.	0.5	11
99	A 24-Week, Multicenter, Open-Label, Randomized Study to Compare Changes in Glucose Metabolism in Patients With Schizophrenia Receiving Treatment With Olanzapine, Quetiapine, or Risperidone. Journal of Clinical Psychiatry, 2009, 70, 487-499.	2.2	49
100	Deficits in facial affect recognition in unaffected siblings of Xhosa schizophrenia patients: Evidence for a neurocognitive endophenotype. Schizophrenia Research, 2008, 99, 270-273.	2.0	53
101	Bilingualism and psychosis: A case report. Schizophrenia Research, 2008, 103, 333-335.	2.0	11
102	Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: Results from a randomized, placebo-controlled trial. Psychiatry Research, 2008, 161, 284-291.	3.3	51
103	Oral versus injectable antipsychotic treatment in early psychosis: Post hoc comparison of two studies. Clinical Therapeutics, 2008, 30, 2378-2386.	2.5	71
104	Psychometric properties of the Multidimensional Scale of Perceived Social Support in youth. Comprehensive Psychiatry, 2008, 49, 195-201.	3.1	227
105	Allocation of attention to the eye and mouth region of faces in schizophrenia patients. Cognitive Neuropsychiatry, 2008, 13, 505-519.	1.3	4
106	Mass Murders: Implications for Mental Health Professionals. International Journal of Psychiatry in Medicine, 2008, 38, 261-269.	1.8	29
107	Predictors of long-term outcome in schizophrenia. Current Opinion in Psychiatry, 2008, 21, 173-177.	6.3	87
108	Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. International Clinical Psychopharmacology, 2008, 23, 325-331.	1.7	84

#	ARTICLE	IF	CITATIONS
109	Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 210-213.	1.4	87
110	Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. <i>International Clinical Psychopharmacology</i> , 2008, 23, 343-356.	1.7	75
111	The 15th Biannual National Congress of the South African Society of Psychiatrists, 10-14 August 2008, Fancourt, George, W Cape. <i>South African Journal of Psychiatry</i> , 2008, 14, 18.	0.4	0
112	Poor insight increases relapse and re-admission to hospital in people with non-affective psychosis. <i>Evidence-Based Mental Health</i> , 2007, 10, 106-106.	4.5	1
113	Long-Acting Formulations of Atypical Antipsychotics. <i>CNS Drugs</i> , 2007, 21, 441-448.	5.9	52
114	Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates. <i>Schizophrenia Research</i> , 2007, 89, 129-139.	2.0	180
115	Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study. <i>Schizophrenia Research</i> , 2007, 93, 117-130.	2.0	224
116	The relationships between antipsychotic dose and efficacy, and the time to treatment response. <i>Psychiatrie Und Psychotherapie</i> , 2007, 3, 9-13.	0.0	0
117	The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial. <i>Schizophrenia Research</i> , 2006, 84, 112-120.	2.0	83
118	Time Course for Antipsychotic Treatment Response in First-Episode Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 743.	7.2	86
119	Remission in First-Episode Psychosis. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1707-1712.	2.2	88
120	The relationships between depression and remission in first-episode psychosis. <i>World Psychiatry</i> , 2006, 5, 172-6.	10.4	25
121	Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 175-182.	2.1	21
122	Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial. <i>American Journal of Psychiatry</i> , 2005, 162, 947-953.	7.2	331
123	Neurological abnormalities in first-episode schizophrenia: temporal stability and clinical and outcome correlates. <i>Schizophrenia Research</i> , 2005, 75, 35-44.	2.0	62
124	Positive and negative symptoms in affected sib pairs with schizophrenia: Implications for genetic studies in an African Xhosa sample. <i>Schizophrenia Research</i> , 2005, 79, 239-249.	2.0	25
125	13th National Congress of the South African Society of Psychiatrists, 20-23 September 2004. <i>South African Journal of Psychiatry</i> , 2004, 10, 17.	0.4	3
126	Practical Application of Pharmacotherapy With Long-Acting Risperidone for Patients With Schizophrenia. <i>Psychiatric Services</i> , 2004, 55, 997-1005.	2.0	69



#	ARTICLE	IF	CITATIONS
127	Evidence-based pharmacotherapy of schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 219-238.	2.1	19
128	A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 125-131.	2.1	52
129	A Single-Blind, Randomized Trial Comparing Quetiapine and Haloperidol in the Treatment of Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 696-701.	2.2	89
130	Health care discrimination against the mentally ill—a comparison of private health insurance benefits for major depressive disorder and ischaemic heart disease in South Africa. <i>South African Medical Journal</i> , 2004, 94, 821-3.	0.6	0
131	The new and evolving pharmacotherapy of schizophrenia. <i>Psychiatric Clinics of North America</i> , 2003, 26, 141-163.	1.3	23
132	The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. <i>Schizophrenia Research</i> , 2003, 61, 47-57.	2.0	329
133	Clinical Potential of Omega-3 Fatty Acids in the Treatment of Schizophrenia. <i>CNS Drugs</i> , 2003, 17, 1081-1091.	5.9	53
134	Randomized, Placebo-Controlled Study of Ethyl-Eicosapentaenoic Acid as Supplemental Treatment in Schizophrenia. <i>American Journal of Psychiatry</i> , 2002, 159, 1596-1598.	7.2	257
135	Focus on psychiatry in South Africa. <i>British Journal of Psychiatry</i> , 2001, 178, 382-386.	2.8	43
136	Anxiety symptoms in schizophrenia: the need for heightened clinician awareness. <i>Primary Care and Community Psychiatry</i> , 2001, 7, 25-29.	0.4	6
137	MAGNETIC RESONANCE IMAGING IN ALCOHOLIC KORSAKOFF'S SYNDROME: EVIDENCE FOR AN ASSOCIATION WITH ALCOHOLIC DEMENTIA. <i>Alcohol and Alcoholism</i> , 1996, 31, 479-486.	1.6	25
138	Disordered Water Homeostasis in Schizophrenia and Cerebral Ventricular Size. <i>British Journal of Psychiatry</i> , 1995, 166, 501-506.	2.8	12
139	The one-month prevalence and correlates of psychotic-like experiences in the general adult population in Nigeria. <i>Current Psychology</i> , 0, , .	2.8	2